Alberto Sobrero's guest appearances

Alberto Sobrero

HMP CME (Video)

HMP CME (Audio)

ESMO 14th World Congress on Gastrointestinal Cancer

Josep Tabernero

Michel Ducreux

Fortunato Ciardiello

Sonia Friedman

Robert Sidbury

Jonathan Kay

Richard Kim

Stanley Cohen

Matt S

Atopic Dermatitis

Axel Grothey

Tanios Bekaii-Saab

Ghassan Abou-Alfa

Heinz-Josef Lenz

Rakesh Jain

OwlTail

Webcast: ESMO 20th World Congress on Gastrointestinal Cancer

Alberto Sobrero: Clinical interpretation and validity of clinical trials: When do they become practice changing?

Prof Alberto Sobrero talks to ecancertv at the ESMO 14th World Congress on Gastrointestinal Cancer in Barcelona about the CORRECT phase III study with the oral multi-kinase inhibitor regorafenib. The study showed a significant overall survival benefit in favour of regorafenib versus placebo in patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies. In addition to talking about the trial’s findings and their significance, Prof Sobrero looks at the features that could set regorafenib from other molecularly-targeted treatments for mCRC. He also notes that regorafenib has just been given priory review status by the Food and Drug Administration, which means that the drug could be available in the US within 6 months rather than the usual 10-12 months if it proves successful.

Prof Alberto Sobrero talks to ecancertv at the ESMO 14th World Congress on Gastrointestinal Cancer in Barcelona about the CORRECT phase III study with the oral multi-kinase inhibitor regorafenib. The study showed a significant overall survival benefit in favour of regorafenib versus placebo in patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies. In addition to talking about the trial’s findings and their significance, Prof Sobrero looks at the features that could set regorafenib from other molecularly-targeted treatments for mCRC. He also notes that regorafenib has just been given priory review status by the Food and Drug Administration, which means that the drug could be available in the US within 6 months rather than the usual 10-12 months if it proves successful.

CORRECT study data prompts US FDA priority review: Prof Alberto Sobrero – Ospedale San Martino, Genova, Italy